Using tiny particles to improve radiation treatment for a type of brain cancer in children
Harnessing Extracellular Vesicles to Overcome Radiation Resistance in Pediatric Diffuse Midline Glioma
This study is looking at a type of brain tumor in kids that doesn't respond well to radiation treatment, and it's exploring how tiny particles released by the tumor might help us find better ways to make the radiation work more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10990146 on NIH RePORTER |
What this research studies
This research focuses on pediatric diffuse midline gliomas with a specific genetic alteration that makes them resistant to radiation therapy. The study aims to understand how extracellular vesicles, which are small particles released by tumor cells, contribute to this resistance and how they can be used to deliver new treatments that enhance the effectiveness of radiation. By investigating the role of these vesicles and their contents, particularly microRNAs, the research seeks to develop innovative strategies to sensitize these tumors to existing therapies. This approach combines engineering and cancer biology to potentially improve outcomes for affected children.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old diagnosed with diffuse midline gliomas that have the H3K27M genetic alteration.
Not a fit: Patients with other types of brain tumors or those over the age of 11 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for a deadly form of pediatric brain cancer, improving survival rates and quality of life for young patients.
How similar studies have performed: While the use of extracellular vesicles in cancer treatment is a growing field, this specific approach targeting radiation resistance in pediatric gliomas is novel and has not been extensively tested.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Oza, Viral — University of Kentucky
- Study coordinator: Oza, Viral
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.